Novo Holdings takes the lead in investment in new Asian company

Novo Holdings has taken part in a USD 125m investment in Hummingbird Bioscience, one of the first investments which the fund has made through its new Asian department.

Photo: Novo Holdings / PR

Novo Holdings has led a series C investment round at biotech company Hummingbird Bioscience which is headquartered in Singapore and the US.

Hummingbird is one of the first investments made by Novo Holdings in a privately-held company in Asia. Earlier this year, the holding company invested in the Indonesian company Halodoc which has garnered attention for its digital health platform.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Sanofi reduces US insulin prices for the uninsured

While bills to introduce a price cap on insulin are being discussed in the US Senate, Sanofi has beaten them to the punch and reduced the price of insulin products for US diabetes patients without insurance.

Further reading

Related articles

Latest news

See all jobs